KLOW 80 mg Peptide Blend | Pure Lab Peptides Supply
Product Overview
KLOW 80 mg is a four-component peptide blend supplied as lyophilized powder in one boxed 3 mL vial for laboratory research. Available through Pure Lab Peptides Supply, this formulation combines GHK-Cu, TB-500, BPC-157, and KPV in specified labeled amounts.
The blend contains 80 mg of total labeled components per vial. Each ingredient has distinct molecular characteristics and has been investigated separately in scientific research involving cellular processes, peptide characterization, and biological signaling.
Researchers should evaluate the complete formulation, individual component identities, and available analytical documentation before comparing this blend with other research materials.
KLOW 80 mg Composition and Product Information
- Product name: KLOW 80 mg peptide blend
- Total labeled quantity: 80 mg per vial
- Physical presentation: Lyophilized powder
- Packaging: One boxed vial
- Vial capacity: 3 mL
- Number of labeled components: Four
Component Breakdown
| Component | Labeled amount per vial |
|---|---|
| GHK-Cu | 50 mg |
| TB-500 | 10 mg |
| BPC-157 | 10 mg |
| KPV | 10 mg |
| Total | 80 mg |
These quantities represent the component amounts stated in the product description. The total labeled blend amount is distinct from the vial’s 3 mL capacity, which describes the container rather than an included liquid volume or solution concentration.
KLOW vs. GLOW 70 mg Peptide Blend
KLOW 80 mg differs from the GLOW 70 mg blend by including an additional 10 mg of KPV, according to the listed formulations. The stated amounts of GHK-Cu, TB-500, and BPC-157 remain unchanged.
This distinction concerns composition rather than demonstrated effectiveness. A larger total labeled quantity does not independently establish greater purity, potency, or biological activity.
The GHK-Cu component is a copper-peptide complex. Its stated 50 mg quantity refers to the complete complex rather than 50 mg of elemental copper alone. Researchers comparing formulations should account for the documented chemical form and ingredient proportions.
For a separate presentation, review the GHK-Cu 50 mg product. A standalone component and a premixed blend represent different research materials and should not automatically be treated as equivalent controls.
Scientific Research on KLOW Blend Components
GHK-Cu: Peptide-Copper Complex Research
GHK-Cu is a copper-peptide complex investigated in laboratory studies involving cellular processes and extracellular matrix components.
Maquart and colleagues reported increased collagen synthesis in fibroblast cultures exposed to GHK-Cu. Their findings describe a response observed under specific experimental conditions and do not establish the performance of a commercial KLOW blend.
The GHK-Cu component is identified in the supplied product description by CAS 89030-95-5. Researchers should verify the chemical identity and relevant analytical results against the applicable product documentation.
BPC-157: Experimental Cell Research
BPC-157 has been investigated in preclinical research involving cellular and tissue-related processes. Some experiments have examined migration in rat-derived tendon cells.
These findings provide context for studying the individual compound but do not establish the same response in a four-component mixture. Experimental model, material identity, and measured endpoint remain important when comparing published findings.
TB-500: Molecular Identity and Characterization
The product description identifies TB-500 as full-length, N-acetylated thymosin beta-4, a 43-amino-acid peptide associated with CAS 77591-33-4.
Molecular identity matters when interpreting analytical research. Studies examining fragments of thymosin beta-4 or other related preparations do not automatically characterize the full-length component listed in this formulation.
Researchers should therefore distinguish the specified peptide sequence and chemical modifications from findings obtained using different molecular fragments.
KPV: Peptide Transport and Inflammatory Signaling Research
KPV is a tripeptide investigated in laboratory studies involving peptide transport and inflammatory signaling. Research by Dalmasso and colleagues examined KPV transport through PepT1 and related cellular responses in intestinal and immune-cell models.
Those findings concern the individual peptide under the tested conditions. They do not demonstrate that KPV produces the same effects when combined with GHK-Cu, TB-500, and BPC-157.
Interpreting the Four-Component Formulation
KLOW combines four separately identified components in a single labeled formulation. Although individual ingredients have been investigated in different research settings, findings from one component cannot establish the properties of the complete mixture.
A rigorous comparison should distinguish ingredient identity, measured content, chromatographic purity, and experimental activity. Claims of synergy or improved performance require direct evidence from studies of the complete formulation rather than extrapolation from individual-component studies.
The specified ingredient proportions also matter when comparing the blend with standalone materials or other catalog formulations.
KLOW 80 mg COA and Product Documentation
Visit the Pure Lab Peptides Supply COA and documentation page to review available analytical records.
When evaluating a certificate of analysis (COA), confirm that the documentation corresponds to the exact KLOW formulation and product lot. Where available, review:
- Identity testing: Evidence used to identify the reported compounds.
- Chromatographic purity: The distribution of detected components under the stated analytical method.
- Component content: Whether the report measures the individual ingredients or only selected components.
- Batch identification: The lot number connecting the documentation to the supplied material.
- Analytical methods: The procedures used to obtain the reported results.
A single purity percentage does not establish the identity and quantity of every ingredient in a multi-component blend. Likewise, a general COA webpage does not independently verify a specific vial unless the corresponding report is available and matches the lot.
Storage and Handling Information
Follow the applicable supplier documentation and laboratory procedures for storage, handling, and material integrity. Requirements should be based on the supplied formulation and its documented chemical characteristics.
The 80 mg labeled total and 3 mL vial capacity describe different product attributes. Neither establishes a solution concentration, shelf life, stability after preparation, or a specific preparation method.
Frequently Asked Questions About KLOW 80 mg
What is KLOW 80 mg?
KLOW 80 mg is a catalog-listed four-component peptide blend containing GHK-Cu 50 mg, TB-500 10 mg, BPC-157 10 mg, and KPV 10 mg per vial, according to the supplied product description.
What are the ingredients in KLOW 80 mg?
The listed formulation contains four components: GHK-Cu, TB-500, BPC-157, and KPV. Their stated amounts total 80 mg per vial.
What is the difference between KLOW 80 mg and GLOW 70 mg?
According to the listed formulations, KLOW contains an additional 10 mg of KPV while the stated amounts of the other three components remain the same. This difference describes the formulation and does not independently establish greater effectiveness.
Is KLOW 80 mg a single peptide?
No. KLOW is described as a blend of four separately identified components rather than a single peptide molecule. Its total labeled amount represents the combined stated quantities of those components.
What does the 3 mL vial size mean?
The 3 mL figure describes the vial’s capacity. It does not establish the volume of liquid supplied or indicate a solution concentration.
What should I check in a KLOW COA?
Review the product identity, matching lot number, analytical methods, purity results, and component-content measurements where available. For a multi-component blend, determine whether the documentation evaluates each ingredient separately.
Do studies of the individual ingredients prove that KLOW is effective?
No. Studies of individual compounds provide scientific context but do not establish the effects, synergy, or performance of the complete four-component blend. Those conclusions require appropriate direct evidence.
Where can I find KLOW product documentation?
Visit Pure Lab Peptides Supply for supplier information and the COA and document page to review available records. Verify the specific product and batch before interpreting a report.
Research Documentation and Product Review
KLOW 80 mg is listed as a four-component peptide blend supplied as lyophilized powder in a boxed 3 mL vial. Its labeled composition, component identities, and batch-specific analytical documentation provide the basis for evaluating the material in a laboratory research context.
Explore Pure Lab Peptides Supply for supplier information, compare the GLOW 70 mg blend where relevant, and consult the available COA documentation when reviewing product records.
Research-use statement: This description provides scientific and material-identification information. It does not establish suitability for human or veterinary use, diagnose or treat a medical condition, or guarantee a particular experimental outcome.

















